Transcriptome Analyses Identify a Metabolic Gene Signature Indicative of Dedifferentiation of Papillary Thyroid Cancer

• DOI: 10.1210/jc.2018-02686
• Publication Date: 2019-04-03T09:25:05Z
• Authors: Ben Ma; Hongyi Jiang; Duo Wen; Jiaqian Hu; Litao Han; Wanlin Liu; Weibo Xu; Xiao Shi; Wenjun Wei; Tian Liao; Yulong Wang; Zhongwu Lu; Yu Wang; Qinghai Ji
• Keywords: Gene signature

Abstract Context Metabolic reprogramming is a common feature of tumorigenesis. It remains unknown concerning the expression pattern metabolism-associated genes in dedifferentiated thyroid cancer (DDTC). Objective This study aimed to identify useful signature indicate dedifferentiation papillary (PTC). Design and Setting We used one discovery two validation cohorts screen out aberrant metabolic DDTC, further The Cancer Genome Atlas (TCGA) cohort search for independent risk factors low-differentiated phenotype PTC as dedifferentiation. prediction DDTC was validated TCGA combined Gene Expression Omnibus cohort. also analyzed correlations score with clinicopathological features PTC. set enrichment analyses were performed Results Significant pathways correlated differentiation status A including LPCAT2, ACOT7, HSD17B8, PDE8B, ST3GAL1 discovered across three cohorts. not only predictive but significantly associated BRAFV600E mutation (P < 0.001), T3/T4 stage extrathyroidal extension lymph node metastasis tumor/lymph node/metastasis III/IV 0.001) Downregulations LPCAT2 = 0.009) 0.005) increased risks decreased disease-free survival patients. Furthermore, implicated number oncogenic biological pathways. Conclusions Our findings suggest that deregulations mediate PTC, gene can be biomarker DDTC.